Compare Adaptive Biotechnologies Corp (ADPT) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs KKR & Co Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.23 (market cap $3.33B), while KKR & Co Inc trades at $92.97 (market cap $85.42B). The key difference: KKR & Co Inc is far larger — about 25.7× Adaptive Biotechnologies Corp's market cap, and KKR & Co Inc pays a 0.79% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | KKR | |
|---|---|---|
Market Cap | $3.33B | $85.42B |
Sector | Health | Financials |
52-Week High | $22.37 | $152.16 |
52-Week Low | $10.24 | $83.88 |
Enterprise Value | $3.19B | $10.95B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
KKR trades at $95.14, up 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows strong analyst sentiment with 24 buy ratings and a consensus price target of $127.43. Recent developments include a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, highlighting strategic growth initiatives. Financials reveal a P/E of 32.64 and net income margin of 14.51%, with Q1 2026 EPS beating expectations at $1.39 versus $1.26 estimated.
The outlook for KKR is positive, driven by expansion in renewable energy and private credit leadership, though risks include integration challenges from acquisitions and market volatility. Earnings growth and strategic deals present upside potential, with the current price offering a 34% discount to the analyst target. Investors should monitor Q2 2026 results due July 30, 2026, for further catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
